Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives gross proceeds of approximately SEK 265 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is inter alia to enhance the company’s financial position ahead of negotiating a deal pertaining to its lead product HyNap-Dasa and to continue to expand the company’s product portfolio.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström, Joel Magnusson and Linnea Petersson.

Related

Vinge represents Cinven in connection with the acquisition of Ongoing Warehouse

Vinge has represented the international private equity firm Cinven in connection with its acquisition of Ongoing Warehouse.
May 06, 2026

Vinge advises Fazer in connection with its acquisition of Aroma

Fazer has entered into an agreement to acquire Konfektyrfabriken Aroma AB, a Swedish confectionery manufacturer known for its classic candy products such as Geléhallon, Hallonbåtar, Röda Hjärtan and Gräddkola. The acquisition strengthens Fazer's position in the Swedish confectionery market, particularly within pick & mix, packed candy, and seasonal products. The acquisition is subject to customary regulatory approvals.
May 06, 2026

Vinge represents Investor in connection with Electrolux Group’s rights issue

Vinge represents Investor AB (publ) (“Investor”) in connection with Electrolux Group’s rights issue of approximately SEK 9 billion. Investor has undertaken to subscribe for Investor’s pro rata share, corresponding to approximately SEK 1.7 billion, and in addition to guarantee approximately SEK 1.7 billion.
May 06, 2026